# SALKALLI- retatrutide lyophilized powder 7.5mg injection, powder, lyophilized, for solution

**Guangzhou Yixin Cross-border E-commerce Co., Ltd.** 

-----

## Active ingredients (in each kit)

Retatrutide 7.5 mg (lyophilized powder)
Sterile Water for Injection 0.75 mL

## **Purpose**

Antidiabetic / Weight management agent

Diluent

### Uses

Helps control blood sugar in adults with type 2 diabetes (when prescribed). Intended to assist adults with weight loss as directed by a healthcare provider.

## Warnings — Read carefully and tell your doctor if any apply to you.

Pancreatitis: Cases of pancreatitis have been reported. If you have severe abdominal pain (that may spread to the back), persistent vomiting, or signs of pancreatitis — stop using and contact your healthcare provider immediately.

Allergic reaction: Serious allergic reactions have been reported. Stop use and seek emergency care if you have hives, swelling of face/lips/tongue/throat, or trouble breathing.

Serious gastrointestinal disease: May cause GI adverse reactions. Not recommended for patients with severe GI disease (not studied).

Acute gallbladder disease: Cases (e.g., gallstones) have been reported. If you experience severe right-upper-abdominal pain or jaundice, seek medical evaluation.

Hypoglycemia warning: Do not use RETATRUTIDE if you have a history of recurrent or severe hypoglycemia. RETATRUTIDE may further lower blood glucose levels. Use is contraindicated in individuals with baseline hypoglycemia or conditions predisposing to hypoglycemia.

Pregnancy or breastfeeding: Do not use.

Children: Do not use.

Drug Interactions / Precautions

Other antidiabetic medications: Retatrutide lowers blood glucose. Using it with insulin or sulfonylureas may increase the risk of hypoglycemia. Blood glucose should be closely monitored; doses of other antidiabetic drugs may need adjustment.

Drugs affecting gastrointestinal motility: Retatrutide may delay gastric emptying. Coadministration with prokinetic agents (e.g., domperidone) or antacids may alter absorption or worsen GI discomfort. Cardiovascular medications: Caution with statins, digoxin, or warfarin.

Statins: absorption may be affected; monitor lipid levels.

Warfarin: changes in metabolism may alter anticoagulant effects; monitor INR levels.

General precautions: Retatrutide should be used only under medical supervision. Inform your healthcare provider about all medications, including prescription, over-the-counter, and herbal products.

Possible side effects

Nausea, diarrhea, decreased appetite, vomiting, constipation, dyspepsia (indigestion), abdominal pain. If side effects are severe or persistent, contact your healthcare provider.

When to stop and call your doctor

If you develop severe abdominal pain (possible pancreatitis), severe allergic reaction, jaundice, or other serious symptoms.

## **Directions — Preparation & Dosing (basic patient summary)**

Concentration after reconstitution (calculation):

 $10 \text{ mg} \div 1 \text{ mL} = 10 \text{ mg/mL}.$ 

Therefore: 0.25 mL = 2.5 mg; 0.5 mL = 5 mg; 0.75 mL = 7.5 mg; 1 mL = 10 mg.

Typical weekly dosing schedule (example shown — follow your prescriber):

Weeks 1-4: 0.25 mL (2.5 mg) once weekly (subcutaneous)

Weeks 5-8: 0.5 mL (5 mg) once weekly

Weeks 9-12: 0.75 mL (7.5 mg) once weekly

Week 13 and onward: 1 mL (10 mg) once weekly

One carton (4 kits) provides 4 weekly doses.

How to prepare and inject (patient summary):

Wash hands with soap and water. Inspect vials for damage.

Using aseptic technique, withdraw the prescribed volume (in mL) of Sterile Water for Injection into a sterile syringe. Inject the diluent into the vial containing the lyophilized powder.

Gently swirl the vial until the powder fully dissolves. Do not shake vigorously. Solution should be clear; do not use if cloudy or particulate present.

Withdraw the prescribed volume (e.g., 0.25, 0.5, 0.75 or 1 mL) into a sterile syringe and inject subcutaneously in the abdomen, thigh, or upper arm after cleaning the site with alcohol. Rotate injection sites.

Dispose of syringe/needle in an appropriate sharps container.

### Do not use

Other antidiabetic medications: Retatrutide lowers blood glucose. Using it with insulin or sulfonylureas may increase the risk of hypoglycemia. Blood glucose should be closely monitored; doses of other antidiabetic drugs may need adjustment.

Drugs affecting gastrointestinal motility: Retatrutide may delay gastric emptying. Co-

administration with prokinetic agents (e.g., domperidone) or antacids may alter absorption or worsen GI discomfort.

Cardiovascular medications: Caution with statins, digoxin, or warfarin.

Statins: absorption may be affected; monitor lipid levels.

Warfarin: changes in metabolism may alter anticoagulant effects; monitor INR levels.

General precautions: Retatrutide should be used only under medical supervision. Inform your healthcare provider about all medications, including prescription, over-the-counter, and herbal products.

## When using section

Pancreatitis: Cases of pancreatitis have been reported. If you have severe abdominal pain (that may spread to the back), persistent vomiting, or signs of pancreatitis — stop using and contact your healthcare provider immediately.

Allergic reaction: Serious allergic reactions have been reported. Stop use and seek emergency care if you have hives, swelling of face/lips/tongue/throat, or trouble breathing.

Serious gastrointestinal disease: May cause GI adverse reactions. Not recommended for patients with severe GI disease (not studied).

Acute gallbladder disease: Cases (e.g., gallstones) have been reported. If you experience severe right-upper-abdominal pain or jaundice, seek medical evaluation.

Hypoglycemia warning: Do not use RETATRUTIDE if you have a history of recurrent or severe hypoglycemia. RETATRUTIDE may further lower blood glucose levels. Use is contraindicated in individuals with baseline hypoglycemia or conditions predisposing to hypoglycemia.

Pregnancy or breastfeeding: Do not use.

Children: Do not use.

Drug Interactions / Precautions

Other antidiabetic medications: Retatrutide lowers blood glucose. Using it with insulin or sulfonylureas may increase the risk of hypoglycemia. Blood glucose should be closely monitored; doses of other antidiabetic drugs may need adjustment.

Drugs affecting gastrointestinal motility: Retatrutide may delay gastric emptying. Coadministration with prokinetic agents (e.g., domperidone) or antacids may alter absorption or worsen GI discomfort.

Cardiovascular medications: Caution with statins, digoxin, or warfarin.

Statins: absorption may be affected; monitor lipid levels.

Warfarin: changes in metabolism may alter anticoagulant effects; monitor INR levels.

General precautions: Retatrutide should be used only under medical supervision. Inform your healthcare provider about all medications, including prescription, over-the-counter, and herbal products.

Possible side effects

Nausea, diarrhea, decreased appetite, vomiting, constipation, dyspepsia (indigestion), abdominal pain. If side effects are severe or persistent, contact your healthcare provider.

When to stop and call your doctor

If you develop severe abdominal pain (possible pancreatitis), severe allergic reaction, jaundice, or other serious symptoms.

## stop use

Pancreatitis: Cases of pancreatitis have been reported. If you have severe abdominal pain (that may spread to the back), persistent vomiting, or signs of pancreatitis — stop using and contact your healthcare provider immediately.

Allergic reaction: Serious allergic reactions have been reported. Stop use and seek emergency care if you have hives, swelling of face/lips/tongue/throat, or trouble breathing.

Serious gastrointestinal disease: May cause GI adverse reactions. Not recommended for patients with severe GI disease (not studied).

Acute gallbladder disease: Cases (e.g., gallstones) have been reported. If you experience severe right-upper-abdominal pain or jaundice, seek medical evaluation.

Hypoglycemia warning: Do not use RETATRUTIDE if you have a history of recurrent or severe hypoglycemia. RETATRUTIDE may further lower blood glucose levels. Use is contraindicated in individuals with baseline hypoglycemia or conditions predisposing to hypoglycemia.

Pregnancy or breastfeeding: Do not use.

Children: Do not use.

Drug Interactions / Precautions

Other antidiabetic medications: Retatrutide lowers blood glucose. Using it with insulin or sulfonylureas may increase the risk of hypoglycemia. Blood glucose should be closely monitored; doses of other antidiabetic drugs may need adjustment.

Drugs affecting gastrointestinal motility: Retatrutide may delay gastric emptying. Coadministration with prokinetic agents (e.g., domperidone) or antacids may alter absorption or worsen GI discomfort.

Cardiovascular medications: Caution with statins, digoxin, or warfarin.

Statins: absorption may be affected; monitor lipid levels.

Warfarin: changes in metabolism may alter anticoagulant effects; monitor INR levels.

General precautions: Retatrutide should be used only under medical supervision. Inform your healthcare provider about all medications, including prescription, over-the-counter, and herbal products.

Possible side effects

Nausea, diarrhea, decreased appetite, vomiting, constipation, dyspepsia (indigestion), abdominal pain. If side effects are severe or persistent, contact your healthcare provider.

When to stop and call your doctor

If you develop severe abdominal pain (possible pancreatitis), severe allergic reaction, jaundice, or other serious symptoms.

## Keep out of reach of children.

Not for use in children.

## **Inactive Ingredients:**


Mannitol, Disodium Hydrogen Phosphate, Sodium Dihydrogen Phosphate, Sodium Chloride, Sodium Bicarbonate.

### PRINCIPAL DISPLAY PANEL




尺寸:200 x 40 x 125 mm

工艺:350g白卡过光膜,四色印,指定位置激凸内托:350g抽盒纸托(按外盒尺寸与产品实物大小调整尺寸槽深)



# 7.5mg冻干减肥注射器-2件套封套 尺寸:200 x 127 x 81 mm

工艺:350g白卡过光膜,四色印





### **Saikaiii**

## Retatrutide (lyophilized powder)

1 set containing 2 cartons (each carton contains 4 kits) 0.75ml: 7.5mg

0.75mL: **7.5**mg

# Salkalli™ R



**USA** 

## Retatrutide (lyophilized powder)

1 set containing 2 cartons (each carton contains 4 kits)

For Reconstitution and Subcutaneous Use Only — Not for IV use Rx Only — Dispense only with prescription

Each kit provides a single weekly dose. One carton provides 4 weekly doses(4-week supply)

Salkalli™ Salkalli™ Retatrutide Sterile Water philized pow for Injectio

Each kit contains: Retatrutide 7.5 mg vial + Sterile Water for Injection 0.75 mL vial + sterile syringe

Store at room temperature below 25 °C (77 °F) before reconstitution. Excursions between 15 °C and 30 °C (59 °F and 86 °F) are permitted. After mixing, refrigerate at 2–8  $^{\circ}$ C (36–46  $^{\circ}$ F) and use within 24 hours per vial.

See enclosed leaflet for full instructions.



Solitality

Company address line 1]

(Company address line 1]

(City, State, Country)

Customer Service: [phone] | [email] | [website]

Contents:

1 set containing 2 cartons,
each corton containing 4 complete single-use kits, each kit containing:
1 vial Retartutie 6 25 mg (lyophilized powder)
1 sterile syringe

Storage: Store unused kits at room temperature below 25 °C (77 °F). Excursions between 15 °C and 30 °C (59 °F and 86 °F) are permitted. After reconstitution, refrigerate of 2-8° ( $^{\circ}$ 63-64 °F) and use within 24 hours. Protect from light and moisture. Do not freeze. Keep in original corton until use.

NDC: 00000-000-00. Rx Only. For prescription use only. Not for sale

0.75ml: 7.5mg

## DRUG FACTS — For Patient Use (Prescription)

Active ingredients (in each kit)
Retatrutide 7.5 mg (lyophilized powder)
Sterile Water for Injection 0.75 mL

**Purpose**- Antidiabetic / Weight management agent
- Diluent

## Warnings — Read carefully and tell your doctor if any apply to you.

- Formandisco, color of Jones very law or sector of your years you by the Jones very law of Jones very law of the energeted. If you have severe disclaminal pain contact your healthcare provided immediately.

  Allegic records resistant ellegic records have been reported to Stop used good contact your healthcare provided immediately.

  Allegic records resistant ellegic records have been reported to Stop used and seek emergency care if you have hives, swelling of focallipathrouguelthroat, or trouble breathing. Serious gestrometrated discusse May couse of other services. Not recommended for patients with severe of discuss not studied.

  Active galliboded reference for studied.

  Active galliboded reference for studied.

  Active galliboded reference for studied and studied and studied several studied and studied with baseline hypoglycemia or conditions predisposing to hypoglycemia.

  Children Do not use.

- Co-ordinistration with proteinses upgeness are assessed in a convenient of discontinuors. Coulous milks stating, dispoin, or workforin.

  Statins obsorption may be offereded, menitor ligit levels.

  Statins obsorption may be offereded menitor ligit levels.

  Several pre-continuors (menitors) in metabolism may obte entitioogudaret effects; menitor INR levels.

  General pre-coultures, Restruició should be used mily under medicol supervision, helemy your healthough protein obten of medicoloring, which pre-copyings over the country, and hefuld should be used to the country of t

### Possible side effects

When to stop and call your doctor

• If you develop severe abdominal pain (possible pancreatitis), severe allergic reaction, jaundice, or other serious symptoms.

### Directions — Preparation & Dosing (basic patient summary)

Concentration after reconstitution (calculation):

• 10 mg + 1 mL = 10 mg/mL.

• Therefore: 0.25 mL = 2.5 mg; 0.5 mL = 5 mg; 0.75 mL = 7.5 mg; 1 mL = 10 mg.

Typical weekly dosing schedule (example shown — follow your prescriber):

• Weeks 1-4: 0.25 mL (25 mg) once weekly (subcutaneous)

- One cortion (4 kHz) provides 4 weekly doses.

  New to propore and inject (potient summary):

  1. Wosh hinds with soop and water, inspect viols for damage.

  2. Wosh hinds with soop and water, inspect viols for damage.

  2. Living agestic featuring, withdraws the prescribed violance (in mil.) of Sterick Water for Injection

  2. Living agestic featuring, withdraws the prescribed violance (in mil.) of Sterick Water for Injection

  3. Gently with the violance of the provider fully disables. Do not shock vigorously, Solution should

  5. Gently with the violance, Injection present.

  4. Withdraw the prescribed violance (e.g., 0.25, 0.5, 10.75 or 1 mil.) into a steelle syringe and inject

  5. Withdraw the prescribed violance (e.g., 0.25, 0.5, 10.75 or 1 mil.) into a steelle syringe and inject

  6. Withdraw the prescribed violance (e.g., 0.25, 0.5, 10.75 or 1 mil.) into a steelle syringe and inject

  6. Withdraw the prescribed violance (e.g., 0.25, 0.5, 10.75 or 1 mil.) into a steelle syringe and inject

  6. Withdraw the prescribed violance (e.g., 0.25, 0.5, 10.75 or 1 mil.) into a steelle syringe and inject

  6. Withdraw the prescribed violance (e.g., 0.25, 0.5, 10.75 or 1 mil.) into a steelle syringe and inject

  6. Withdraw the prescribed violance (e.g., 0.25, 0.5, 10.75 or 1 mil.) into a steelle syringe and inject

  6. Withdraw the prescribed violance (e.g., 0.25, 0.5, 10.75 or 1 mil.) into a steelle syringe and inject

  6. Withdraw the prescribed violance (e.g., 0.25, 0.5, 10.75 or 1 mil.) into a steelle syringe and inject

  6. Withdraw the prescribed violance (e.g., 0.25, 0.5, 10.75 or 1 mil.) into a steelle syringe and inject

  6. Withdraw the prescribed violance (e.g., 0.25, 0.5, 10.75 or 1 mil.) into a steelle syringe and inject

  6. Withdraw the prescribed violance (e.g., 0.25, 0.5, 10.75 or 1 mil.) into a steelle syringe and inject

  6. Withdraw the prescribed violance (e.g., 0.25, 0.5, 10.75 or 1 mil.) into a steelle syringe and inject

  6. Withdraw the prescribed violance (e.g., 0.25, 0.5, 10.75 or 1 mil.) into a steelle syrin

Inactive Ingredients:
Mannitol, Disodium Hydrogen Phosphate, Sodium Dihydrogen Phosphate, Sodium Chloride,
Sodium Bicarbonate.

- Other information


   Store unnest kits at tom temperature below 25 °C (77 °F). Excursions between 15 °C and 30 °C

  97 °F and 86 °P) are permitted. After reconstitution, refrigerate at 2-8°C (164-46 °P) and use width 27 shours. Protect from kight and moistate. Do not feetac. Resp. in original continual use. Proceedings of the control o

# 7.5mg冻干减肥注射器-3件套封套

尺寸:200 x 127 x 122 mm

工艺:350g白卡过光膜,四色印



200mm

## Salkalli™

Retatrutide (lyophilized powder)

1 set containing 3 cartons (each carton contains 4 kits) 0.75ml: 7.5mg

# Salkalli<sup>™</sup> R

## **USA**

## Retatrutide (lyophilized powder)

1 set containing 3 cartons (each carton contains 4 kits)

For Reconstitution and Subcutaneous Use Only — Not for IV use Rx Only — Dispense only with prescription

Each kit provides a single weekly dose. One carton provides 4 weekly doses(4-week supply)



0.75mL: **7.5**mg

Each kit contains: Retatrutide 7.5 mg vial + Sterile Water for Injection 0.75 mL vial + sterile syringe

Store at room temperature below 25 °C (77 °F) before reconstitution. Excursions between 15 °C and 30 °C (59 °F and 86 °F) are permitted. After mixing, refrigerate at 2–8 °C (36–46 °F) and use within 24 hours per vial.

See enclosed leaflet for full instructions.



## Manufactured for: Salkalli™

Salkalli\*\*
[Company address line 1]
[City, State, Country]
Customer Service: [phone] | [email] | [website]

- Customer Service: [phone] [ [email] ] [website]
  Contents:
  1 set containing 3 caratons,
  each carato containing 4 complete single-use kits, each kit containing:
  1 vial Returtutide 7.5 mg (lyophillized powder)
  1 vial Sterille water for injection 0.75 ml.
  1 sterile syringe

Storage: Store unused kits at room temperature below 25 °C (77 °F). Excursions between 15 °C and 30 °C (59 °F and 86 °F) are permitted. After reconstitution, refrigerate at 2-8 °C (35-46 °F) and use within 24 hours. Protect from light and moisture. Do not freeze. Keep in original corton until use

NDC: 00000-000-00. Rx Only. For prescription use only. Not for sale without prescription.

0.75ml: 7.5mg

### DRUG FACTS — For Patient Use (Prescription)

### Active ingredients (in each kit) Retatrutide 7.5 mg (lyophilized powde

Purpose Antidiabetic / Weight management agent Diluent

Uses

- Helps control blood sugar in adults with type 2 diabetes (when prescribed).

- Intended to assist adults with weight loss as directed by a healthcare proving the control of the c

- Intended to assist adults with weight loss as directed by a healthcare provider.

  Warnings Read carefully and tell your doctor if any apply to you.

  \*\*Intercettitis: Costs of paraceutitis lave been regarded. If you have severe addominal pain and contact your healthcare provider immediately.

  \*\*Allergic reaction: Serious aftering reactions have been reported. Stop use and seak-emergency care if you have hives, swelling of facellipstronguithroat, or touble breathing.

  \*\*Serious gasterinetism diseases: May couse of outweer reactions. Not recommended for potients with severe Gi disease (not studied).

  \*\*Acting plittleded decisean: Costs les go, publicates in any other reactions. It is recommended. Acting plittleded decisean: Costs les go, publicates in any other reactions. It is recommended to publicate with severe Gi disease for the serious costs of the serious serious contact in the serious serious contact in the serious serious

- \*\*Chaldern to not use.

  \*\*Dray Interaction\*\* Precuration\*\*

  \*\*Other antidabetic medications Retarratise lowers blood glucose. Using it with insulin or authorized the medications retained by the state of the state

## Possible side effects Nousea diameter

When to stop and call your doctor

If you develop severe abdominal pain (possible pancreatitis), severe allergic reaction, jaundice, or other serious symptoms.

### Directions — Preparation & Dosing (basic patient summary)

Concentration ofter reconstitution (calculation):

• 10 mg + 1 mL = 10 mg/mL.

• Therefore: 0.25 mL = 2.5 mg; 0.5 mL = 5 mg; 0.75 mL = 7.5 mg; 1 mL = 10 mg.

- Typical weekly (soling scheduls (grouple ushown follow your prescriber):
  Weekles 1-40. Dis Call goal goes exceeding
  Weekles 5-6. OS m. (S mg) once weekly
  Weekles 5-6. OS m. (I S mg) once weekly
  Weekles 5-70. OS m. (I S mg) once weekly
  Weekles 5-70. OS m. (I S mg) once weekly
  Weekles 5-70. OS provides 4 weekley
  Once carroin (4 kill provides 4 weekley) doese.

- New York was go violent \*\* weekly violent \*\*.

  \*\*New to praper and inject (patient summary):

  1. Wosh hinds with soop and water, inspect viole for damage.

  2. Using agestic textural, withdraw the prescribed volume (in mit,) of Sterile Water for Injection into a selfie syringe. If yet, the falsent into the violent containing the yophildrad product into a selfie syringe. If yet, the falsent into the violent self selfies with a selfies of the violent selfies with the selfies of the violent selfies with the selfies of the violent selfies with the violent selfies of the violent selfies with a selfies yield product selfies with a selfies with a selfies yield selfies with a selfi

Inactive Ingredients:
Mannitol, Disodium Hydrogen Phosphate, Sodium Dihydrogen Phosphate, Sodium Chloride,
Sodium Bicarbonate.

- Other information

  Store unseed sits or come temperature below 25 °C (77 °F). Excursions between 15 °C and 30 °C
  (97 °F and 86 °F) are permitted. After reconstitution, refrigerate at 2-6 °C (56-46 °F) and use
  (97 °F and 86 °F) are permitted. After reconstitution, refrigerate at 2-6 °C (56-46 °F) and use
  (56-1) its is single-use. Discard any unused solution.

  Keep or Lore for of children.

  For questions, contact. Solubill' Customer Care: [phone / email / website insert). To report
  side effects, (and un healthcase providers).

7.5mg冻干减肥注射器-4件套封套 尺寸:200 x 127 x 162 mm 工艺:350g白卡过光膜,四色印



200mm

## Salkalli™

## Retatrutide (lyophilized powder)

1 set containing 4 cartons (each carton contains 4 kits)

0.75ml: 7.5mg

# Salkalli<sup>™</sup> <sup>R</sup><sub>x</sub>



**USA** 

## Retatrutide (lyophilized powder)

1 set containing 4 cartons (each carton contains 4 kits)

For Reconstitution and Subcutaneous Use Only — Not for IV use **Rx Only** — Dispense only with prescription

Each kit provides a single weekly dose. One carton provides 4 weekly doses(4-week supply)

Salkalli™ Salkalli<sup>1</sup> Retatrutide Sterile Water philized pow for Injectio 0.75mL: 7.5mg

# Each kit contains: Retatrutide 7.5 mg vial + Sterile Water for Injection 0.75 mL vial + sterile syringe

Store at room temperature below 25 °C (77 °F) before reconstitution. Excursions between 15 °C and 30 °C (59 °F and 86 °F) are permitted. After mixing, refrigerate at 2–8 °C (36–46 °F) and use within 24 hours per vial.

See enclosed leaflet for full instructions.



Manufactured for:
Salkalli\*
[Company address line 1]
[City, State, Country]
Customer Service: [plone] | [email] | [website]
Contents:
1 set containing 4 carrons,
each corton containing 4 complete single-use kits, each kit containing:
1 vial Returturble 7.5 mg (tyophilized powder)
1 vial Sterile Water for injection 0.75 mL
1 sterile symrage

Storage: Store unused kits at room temperature below 25 °C (77 °F). Excursions between 15 °C and 30 °C (59 °F and 86 °F) are permitted. After reconstitution, refrigerate at 2-8 °C (36-46 °F) and use within 24 hours. Protect from light and moisture. Do not freeze. Keep in original corton until use

NDC: 00000-000-00. Rx Only. For prescription use only. Not for sale without prescription.

0.75ml: 7.5mg

DRUG FACTS — For Patient Use (Prescription)  Active ingredients (In each kit)  Returnstee 7.5 m 01 hospilited ponder)	obdominal pain. If side effects are severe or persistent, contact your healthcare provider.  When to stop and call your doctor  If you develop severe addominal pain (possible pancreatitis), severe allergic reaction, jounder, or other serious symptoms.	
Sterile Water for Injection 0.75 mL Diluent	Directions — Preparation & Dosing (basic patient summary)	
ses Helps control blood sugar in adults with type 2 diabetes (when prescribed), Intended to assist adults with weight loss as directed by a healthcore provider.	Concentration after reconstitution (calculation):  • 10 mg ÷ 1 mL = 10 mg/mL.  • Thereforce 0.25 mL = 2.5 mg; 0.5 mL = 5 mg; 0.75 mL = 7.5 mg; 1 mL = 10 mg.	
Identifies — Read carefully and full your destar If any raphy to you.  **Personatives: Consider hypocomism has been reported. If you have been sededomined poin that may seried to the books, been selected and the control when the production of the	Typical weekly dasing schedule (example shown — follow your prescriber):  "Whether 1-0.25 mL (25 mg) cores weekly subcutaneous)  "Weeks 1-0.25 mL (25 mg) cores weekly  "Weeks 1-0.275 mL (25 mg) cores weekly  "Week 15 and orwand: 1 mL (10 mg) cores weekly One control (4 kts) provides 4 weekly doses.	
	How to propore and fuject [patient summery]:  1. Wosh home with soop and work inspect vide for domage.  2. Using oneptic berhingus, withdrow the prescribed volume (in nt.) of Sterile Water for Injection into a sterile symple, leject to desure into the volume (in nt.) of Sterile Water for Injection into a sterile symple symple to desure into the volume of a facility of the sterile provided be done; do not use if cloudy or particulate present.  4. Windrow the prescribed volume (e.g. 0.25, 6, 0.75 or 1 nt.) lation a sterile symple and injection state.  State and of the sterile symbol sterile symbol state of the	
	Inactive Ingredients: Mannitol, Disodium Hydrogen Phosphate, Sodium Dihydrogen Phosphate, Sodium Chloride, Sodium Bicarbonate.	
deministration with prokinetic agents (e.g., demperidors) or articolds may after obsorption creased disconflort. Counties with status, disposit, or veriforin. Nevascular medications. Counties with status, disposit, or veriforin. In ordinary of the counties of the counties of the counties of the counties of the counties. The counties are considered in counties and counties of the counties are counties. Set of the counties are counties of the counties of th	Other information  Store unused kits to room temperature below 25 °C (77 °P). Excusions between 15 °C and 30 °C (97 °Pa and 86 °T) are permitted. After reconstitution, refrigerate at 2-4 °C (154-46 °P) and use (159 °C and 86 °C (159 °C and 86 °C) and 150 °C (154-46 °P) and use (154-46 °C) and (154-46	

# SALKALLI

retatrutide lyophilized powder 7.5mg injection, powder, lyophilized, for solution

Product Information			
Product Type	HUMAN PRESCRIPTION DRUG	Item Code (Source)	NDC:84778-114
Route of Administration	SUBCUTANEOUS		

Active Ingredient/Active Moiety			
Ingredient Name	<b>Basis of Strength</b>	Strength	
RETATRUTIDE (UNII: NOP2Y096GV) (RETATRUTIDE - UNII:NOP2Y096GV)	RETATRUTIDE	7.5 mg in 0.75 mL	

Inactive Ingredients			
Ingredient Name	Strength		
SODIUM BICARBONATE (UNII: 8MDF5V39QO)			
MANNITOL (UNII: 30WL53L36A)			
SODIUM PHOSPHATE, MONOBASIC, UNSPECIFIED FORM (UNII: 3980JIH2SW)			
SODIUM PHOSPHATE, DIBASIC, ANHYDROUS (UNII: 22ADO53M6F)			

**SODIUM CHLORIDE** (UNII: 451W47IQ8X)

Packaging				
#	Item Code	Package Description	Marketing Start Date	Marketing End Date
1	NDC:84778-114- 02	2 in 1 PACKAGE, COMBINATION	10/30/2025	
1		4 in 1 CARTON		
1		0.75 mL in 1 KIT; Type 1: Convenience Kit of Co-Package		
2	NDC:84778-114- 01	4 in 1 CARTON	10/30/2025	
2		0.75 mL in 1 KIT; Type 1: Convenience Kit of Co-Package		
3	NDC:84778-114- 03	3 in 1 PACKAGE, COMBINATION	10/30/2025	
3		4 in 1 CARTON		
3		0.75 mL in 1 KIT; Type 1: Convenience Kit of Co-Package		
4	NDC:84778-114- 04	4 in 1 PACKAGE, COMBINATION	10/30/2025	
4		4 in 1 CARTON		
4		0.75 mL in 1 KIT; Type 1: Convenience Kit of Co-Package		

Marketing Information			
Marketing Category	Application Number or Monograph Citation	Marketing Start Date	Marketing End Date
Export only		10/30/2025	

# **Labeler -** Guangzhou Yixin Cross-border E-commerce Co., Ltd. (455800881)

## **Registrant -** Guangzhou Yixin Cross-border E-commerce Co., Ltd. (455800881)

Establishment				
Na me	Address	ID/FEI	<b>Business Operations</b>	
Guangzhou Yixin Cross-border E-commerce Co., Ltd.		455800881	label(84778-114) , manufacture(84778- 114)	

Revised: 11/2025 Guangzhou Yixin Cross-border E-commerce Co., Ltd.